Greek Firms Seek Drug Ban Reversal

19 March 1997

Greek pharmaceutical manufacturers and importers have requested theMinistry of Social Security to reverse its prohibition on pharmacists from dispensing prescriptions for medicines which include quinolones or third-generation cephalosporins unless the prescription has been accompanied by a sensitivity test (Marketletter March 10).

Industry spokesmen say the ban presents a danger to public health and also to some companies' sales, while providing no financial benefit for the public. Under the decree, pharmacists who do fill prescriptions which are not accompanied by a sensitivity test will not be reimbursed.

Meantime, a Ministry of Health decree has come into effect which states that hospitals will not be allowed to order medicines from suppliers unless they have previously reserved sufficient funds in order to be able to make the payment. This has produced a decline in hospital drug sales, especially of antibiotics, according to reports in the Express and Naftemporiki newspapers.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight